Join

Compare · NVO vs TLSA

NVO vs TLSA

Side-by-side comparison of Novo Nordisk A/S (NVO) and Tiziana Life Sciences Ltd. (TLSA): market cap, price performance, sector, and recent activity on the wire.

Summary

  • Both NVO and TLSA operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
  • NVO is the larger of the two at $183.15B, about 1179.7x TLSA ($155.3M).
  • Over the past year, NVO is down 45.7% and TLSA is down 13.5% - TLSA leads by 32.2 points.
  • NVO has been more active in the news (8 items in the past 4 weeks vs 7 for TLSA).
  • NVO has more recent analyst coverage (25 ratings vs 0 for TLSA).
PerformanceNVO-45.66%TLSA-13.48%
2025-06-09+0.00%2026-06-08
MetricNVOTLSA
Company
Novo Nordisk A/S
Tiziana Life Sciences Ltd.
Price
$41.01-4.51%
$1.22-1.61%
Market cap
$183.15B
$155.3M
1M return
-10.44%
-19.21%
1Y return
-45.66%
-13.48%
Sector
Health Care
Health Care
Industry
Biotechnology: Pharmaceutical Preparations
Biotechnology: Pharmaceutical Preparations
Exchange
NYSE
NASDAQ
IPO
2018
News (4w)
8
7
Recent ratings
25
0
NVO

Novo Nordisk A/S

Novo Nordisk A/S, a healthcare company, engages in the research, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes and Obesity care, and Biopharm. The Diabetes and Obesity care segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral antidiabetic products, obesity, and other chronic diseases. The Biopharmaceuticals segment offers products in the areas of haemophilia, growth disorders, and hormone replacement therapy. The company collaboration agreements with Lund University to develop treatment for Parkinson's diseases; and bluebird bio, Inc. to develop genome editing treatments for children and adult patients. Novo Nordisk A/S also has a research collaboration with Lumen Bioscience, Inc. to explore strategies for delivering oral biologics for cardiometabolic disease. The company was founded in 1923 and is headquartered in Bagsvaerd, Denmark.

TLSA

Tiziana Life Sciences Ltd.

Tiziana Life Sciences Plc, a clinical stage biotechnology company, focuses on the discovery and development of molecules and related diagnostics to treat diseases in oncology and immunology in the United Kingdom. The company's product pipeline includes Foralumab (TZLS-401), a human anti-CD3 monclonal antibody for the treatment of autoimmune and inflammatory diseases, such as GvHD, ulcerative colitis, Crohn's disease, multiple sclerosis, type-1 diabetes, inflammatory bowel diseases, psoriasis, and rheumatoid arthritis; and Milciclib (TZLS-201), which is an orally bioavailable, small molecule inhibitor of cyclin-dependent kinases and Src family kinases for the treatment of hepatocellular carcinoma. It also develops anti-IL6R (TZLS-501), a human anti-interleukin-6 receptor monoclonal antibody for the treatment of IL6-induced inflammation, primarily to treat COVID-19 patients with severe respiratory symptoms. The company was founded in 2013 and is headquartered in London, the United Kingdom. Tiziana Life Sciences Plc is a subsidiary of Planwise Group Limited.

Latest NVO

Latest TLSA